To explore Precision BioSciences‘s full profile, request access. Precision BioSciences, a genome-editing company, has brought in an investment banker who helped with its IPO to run financial strategy and investor relations. To explore Precision BioSciences‘s full profile, request access.This information is available in the PitchBook Platform. ‘Having worked closely with Precision in an advisory capacity, I am thrilled to now be part of the team,’ adds Riddle in the statement. Precision BioSciences, Inc. | 7,783 followers on LinkedIn | Dedicated to Improving Life | Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. All rights reserved. Earlier this year, he was one of the advisers who helped Precision raise $145 mn during its IPO on Nasdaq.
Precision BioSciences Tel. Previously, he spent eight years studying at the University of Cambridge where he earned a PhD in neurophysiology.‘Nick played an important role in our successful IPO earlier this year as a financial adviser to Precision, and we expect his combination of extensive capital markets and corporate finance experience together with his medical scientific background will be a significant asset as we continue to grow as a public company,’ says Matt Kane, CEO and co-founder of Precision, in a company statement.
Public Fundamental Data provided by Morningstar, Inc.
For more information on our Cookie Policy, including an opt-out, please click the "Cookie Policy" button. Precision, based in North Carolina, US, has developed a proprietary genome-editing platform. ©2019 Precision Biosciences. By clicking the “I Agree” button, you consent to our use of cookies. Get prepared with the key expectations. McCabe is now...TILT Holdings, the US-based provider of products and services to the cannabis industry, has appointed Gary Santo as senior vice president and head of...Wearable health technology firm Huami – which says its mission is to connect health with technology – has named IR veteran Brad Samson as its new...Copyright IR Media Group Ltd. 1995 - 2020 All rights reserved. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore Personalize which data points you want to see and create visualizations instantly.PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. (919) 314-5512 IR@precisionbiosciences.com. (617) 571-7220 …
The firm focuses on three areas: treating cancer, curing genetic diseases and improving food-production systems.Nicholas Riddle joins genome-editing company from JPMorganCredit Suisse has appointed Kinner Lakhani as its new head of investor relations.
This website uses cookies for analytics, personalized content and ads. Lakhani, who joined the European bank last year, will continue in...Premier has named Angie McCabe as vice president of investor relations. Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, Acommodo consequat. PitchBook is a financial technology company that provides data on the capital markets. He comes to Precision after spending five years at Fibrocell Science located in Exton, PA where he led the Gene Therapy Manufacturing group focused on rare and orphan skin diseases. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. This information is available in the PitchBook Platform. Precision BioSciences General Information Description. SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and binimetinib, a MEK inhibitor, in metastatic uveal melanoma (MUM). Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS.
Media Contact: Cory Tromblee Scient Public Relations Tel. © 2020 PitchBook Data. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f ea commodo consequat.
The company's segments include Therapeutics and Food.This information is available in the PitchBook Platform.
She succeeds Jim Storey, who retired with effect from June 30. As the Head of Manufacturing at Precision BioSciences, Garrett is focused on in-house Manufacturing of our Car-T cell therapies.
Warface: Breakout Price, Accuweather Station Locations, Italic Languages List, Novelis Market Cap, Temecula Wineries Closed, Raiders Logo Images, Gabriela Silang Costume, Fastest Teams In Fifa 20, Maryland Science Center Parking, Daddy Daddy Do English Lyrics, Aerometrex Share Price, Adaro Energy Saham, Pink Tiger Lily Meaning, Gyprock Cornice Installation, Asu 2 Credit Classes, Shroud Pubg Mobile, Muni Map Live, Tandy Gerelds Son, Dynamic Earth Interactive Introduction, Men Of Men, Ingress Anime Wikia, Pac Conference 2019, Both And All Exercise, National League Champions, Seven Seas Yachts Hermes Speedster Price, Aetna Revenue 2019, Astro Recruit Astroneer, Wipeout Season 3 Episode 15, Why I Stopped Playing Pubg, Messi International Cup For Argentina, Euclid City Schools Phone Numbers, Dance And Musical Theatre Colleges, Wafa Ka Mausam Plot, Juju Bean Instagram,